NewsLetter
Issue 15
2012-10-31

More Details on：www.microport.com.cn
Email：ir@microport.com
Tel (021) 38954600
Fax (021) 50801305

Dr. Martin B. Leon Announced the Latest TARGET I Randomized Controlled Trial Data to the World

Miami,America,23 October, 2012—— At the Next-Generation DES and Bioabsorbable Scaffolds forum of TCT, Dr. Martin B. Leon, professor of Columbia University Medical Center, chairman of TCT, and the principal co-investigator of TARGET, presented the latest primary endpoint data of Firehawk® TARGET I Randomized Controlled Trial ("RCT"). Firehawk® Rapamycin Target Eluting Coronary Stent ("Firehawk®") is the third generation drug-eluting stent system designed and manufactured exclusively by MicroPort Medical. The clinical results approved that Firehawk® is safe and effective. Furthermore it also indicated the feasibility and advantage of the "Target Release" feature on Firehawk®.

TARGET I RCT had enrolled 460 patients (229 in Firehawk® and 231 in Xience V). The RCT has a non-inferiority design with the primary endpoint of the in-stent late lumen loss at 9 months. Angiographic follow-up at 9 months (88.9% follow-up rate) showed that the primary endpoint of the RCT was achieved by 0.13±0.24mm in late lumen loss for Firehawk® and 0.13±0.18mm for Xience V. The non-inferiority is achieved. Furthermore, in the 1 year clinical follow up, there is no evidence of in-stent thrombosis for both Firehawk® and Xience V, and the rate of TLF is 2.2% for both arms.

Dr. Leon pointed out the fact that the unique design of Firehawk® enables lower dosage of drug concentration while maintaining the same efficacy and safety feature that were observed in the previous generation of DES.

At the end of discussions, Dr. Alan Yang, Director of Stanford University Medical Center and the host of this forum, commented on the relationship between polymer degradation time and antiplatelet therapy. Even though the complete polymer degradation time is more than 6 months for Firehawk®, it is still possible to stop anitiplatelet therapy earlier. Since the polymer is only located in the grooves of the abluminal surface, the risk for the remaining polymer to cause late thrombosis is minimized. It would not be a concern for shortening antiplatelet therapy.

Dr. Bo Xu MD, Director of Fu Wai Hospital and National Center for Cardiovascular Diseases of China, agreed with Dr. Alan Yang's opinion. He also mentioned that OCT follow up for Firehawk® FIM study at 4-month indicated endothelial cell coverage is as high as 96.2% which is very impressive.

Four MicroPort Programs Selected as 2012 National Key Technology R&D Program for the 12th Five-year Plan

Shanghai, 29 September, 2012——the STCSM (Science and Technology Commission of Shanghai Municipality) published the results of 2012 National Key Technology R&D Projects. Four MicroPort's projects have been selected and the total applied funds reached 11.1 million RMB.

Shanghai MicroPort Medical (Group) Co., Ltd. submitted the project of Research &Development of Domestic Implantable Dual-chamber Pacemaker System. The project is primarily conducted by MicroPort. Zhongshan Hospital of Fudan University and Renji Hospital，Shanghai Jiao Tong University School of Medicine offer technical support and conduct animal studies and clinical research.

Programs of Trans-septal Guide Catheter R&D and New Type Insulin Pump R&D, submitted by Shanghai MicroPort EP MedTech Co., Ltd. and MicroPort Lifesciences (Shanghai) Co., Ltd. respectively, were selected as the 2012 National Key Technology R&D Projects for the 12th Five-year Plan.

In addition, the project of Drug Coated Intramedullary Nail and Related Key Technology Research, conducted by Shanghai MicroPort Orthopedics Co., Ltd., was also honorably being selected into this project.

The Great Wall International Congress of Cardiology & Asia Pacific Heart Congress

Shanghai, 12 October,2012——At GW-ICC&APHC (the Great Wall International Congress of Cardiology & Asia Pacific Heart Congress), Mr. Bo Xu, MD, Director of Fu Wai Hospital and National Center for Cardiovascular Diseases of China, presented the latest primary endpoint data on behalf of Run-lin Gao, MD, the principal investigator of Firehawk® TARGET I Randomized Controlled Trial (RCT). Firehawk® Rapamycin Target Eluting Coronary Stent is a third generation drug-eluting stent system designed and manufactured by MicroPort Medical.

The experts comment that, with the current published data on Firehawk® TARGET trials, the feasibility and superiority of the "Target Release" feature on Firehawk® stent has been proved. The abluminal groove design of the Firehawk® stent allows the reduced drug content compared to previous generation drug eluting stents. The grooves are only on the outer surface of the struts, and the drug polymer matrix is only stored inside the grooves. This unique design enables lower rapamycin drug dosage by targeting the vessel wall with the goal of minimizing long-term inflammation and decreasing stent thrombosis rate, while maintaining anti-restenosis effect and therapeutic rapamycin level. Firehawk® Rapamycin Target Eluting Coronary Stent System is a new generation drug eluting stent system

501 Newton Rd., ZJ Hi-Tech Park
Shanghai 201203, P. R. China

MicroPort 一个属于医生和病人的品牌 微创医疗

NewsLetter
Issue 15
2012-10-31

More Details on：www.microport.com.cn
Email：ir@microport.com
Tel (021) 38954600
Fax (021) 50801305

with better safety and efficacy.



Mr. Yimin Xu, Vice President of Regulatory and Clinical Affairs of MicroPort, commented the following. “Firehawk® has enrolled 1261 implant cases in premarket clinical trials totally. It is the largest-scale premarket clinical trial of coronary DES in China. In addition, the trial is the first one that in compliance with SFDA’s Clinical Trial Guidelines for Coronary Drug-Eluting Stents (Pending draft for approval).”

2012 Best Customer Service Awarded to MicroPort Lifesciences Shanghai

On September 21th, 2012, MicroPort Lifesciences (Shanghai) Co., Ltd. (“MicroPort Lifesciences”) was awarded as 2012 Best Customer Service---Innovative Service during 2012 China Best Call Center and CRM (Custom Relationship Management) Summit and Award Ceremony. MicroPort Lifesciences receive the customer service award for three years continuously.

Introduced by Xiaobin Yan, the Chairman of CNCBA (China Call Center & BPO Association), the China Best Call Center is the best appraisal institution in customer service field. There have been 400 companies enrolled into the appraisal activity. Outstanding on innovative service, personalized caring and multi communication channels for using of La Fenice® GnRH Infusion Pump, MicroPort Lifesciences was accepted by experts and received the award after a series of rigorous appraisal.

It offered a great opportunity to advertise MicroPort product La Fenice® GnRH Infusion Pump and increase the awareness of the disease of IHH (Idiopathic Hypogonadotropic Hypogonadism) in multi-industry through the China Best Contact Center. Ms. Yin Li, Vice-general Manager of MicroPort Lifesciences, commented on the award that it was an inspiring award that recognizes the effort to help those IHH and Kallmann Syndrome patients in the past year, and she further emphasized that patients are the ones who should receive more attention and supports from the society.

Mustang® Coronary Stent System Re-registered Successfully by SFDA

Shanghai, October 22th, 2012——MicroPort announced that the re-registration of Mustang® Coronary Stent System has been approved by SFDA on September 13th 2012.

Mustang® Coronary Stent System is used with traditional PTCA (balloon angioplasty) to prevent stenosis and improve the function of coronary arteries. The design of large and small sine wave of Mustang® provides better balanced strength and flexibility as well as conformability. Furthermore, the radial force has been further improved by the reinforced design of stiffing-ring structure.

Currently, there are over 80,000 units of Mustang® Coronary Stent System have been sold since the introduction of the product. Mustang® has entered into many countries, such as China, Indonesia, Venezuela, Ecuador, Argentina, Uruguay, Brazil, Peru, Ukraine, Columbia, Philippines and Vietnam.

Tubridge™ Parent Artery Reconstruction Device Initiated Clinical Study

Shanghai, October 28th, 2012——The Opening Ceremony of PARAT (Parent Artery Reconstruction for Large Cerebal Aneurysms using Tubridge™) clinical trial was held successfully in Crowne Plaza Fudan， Shanghai. The purpose of PARAT, a prospective, multicenter, and randomized controlled trial, is to demonstrate the safety and efficacy for the treatment of Large Cerebral Aneurysms of MicroPort next generation vascular reconstruction device, Tubridge™.

PARAT clinical trial is primarily conducted by Changhai Hospital of Shanghai, and co-sponsored by other 13 clinical centers. Professor Jianmin Liu from Changhai Hospital, Professor Zhongxue Wu from Beijing Tiantan Hospital affiliated to Capital Medical University, Professor Peng Zhang from Xuanwu Hospital Capital Medical University, and Professor Chen Yao from Peking University together with other professors attended the Ceremony. During the meeting, the clinical trial protocol was being confirmed and it provided solid foundation for the future development for the trial.

Bo Peng, Chief Marketing Officer of MicroPort, addressed the conference that “After the introduction of APOLLO (Intracranial Stent System) and Willis®(Intracranial Stent Graft System), Tubridge™ Parent Artery Reconstruction device will provide yet another technological advancement in the field of vascular reconstruction and lay a solid foundation for Shanghai MicroPort NeuroTech Co., Ltd, a wholly-owned subsidiary of MicroPort, to become the industry leader in neuro interventional field in China.”

Featured by the dense mesh with high metal coverage, Tubridge™ Parent Artery Reconstruction device is placed at the target aneurysm to reconstruct vessel and to cure the aneurysms by changing the direction of bloodstream. The innovative treatment concept of Tubridge™ benefits those Large Cerebral Aneurysms patients because it prevents high recurrence rate and reduces medical costs.

501 Newton Rd., ZJ Hi-Tech Park
Shanghai 201203, P. R. China